本文字数:2788|预计4分钟读完苦练内功,坚持原研。记者丨韩璐编辑丨谭璐总部在上海的亚盛医药,成为创新药回暖又一个样本。7月10日,公司对外宣布,其自主研发的新型选择性Bcl-2抑制剂利生妥(APG-2575)获批上市,用于治疗成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者。利生妥是首个获批的国产原研Bcl-2抑制剂。而亚盛投入其研发,起于15年前,临床试验又经历了10年。对亚盛...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.